⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Global Orphan Drugs Market Size, Share, Trends, and Forecast 2026-2034 | Market to Reach USD 589.2 Billion as Genomics, Precision Medicine, and Regulatory Incentives Drive Growth
globenewswire.com
AMGN
AZN
GNE
GSK
JNJ
MRK
NVS
PFE
SNY
BMY
REGN
BIIB
GILD
ABBV
EXEL
CRSP
NTLA
EDIT
INCY
VRTX
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
globenewswire.com
INCY
PM360 2026 Trailblazer Awards Winners Announced: Top Companies, Marketers, CEOs, Products, and Initiatives Honored at Gala, Sept. 29th
prnewswire.com
ABT
AZN
CYTK
ARDX
LLY
REGN
NVO
KURA
NOV
BMY
MRK
ARGX
BMRN
TAK
VRTX
GSK
APMD
GKOS
GEN
LAR
ABBV
INCY
GILD
MOD
IQV
PFE
ALGN
SCL
Global Oligonucleotide Synthesis Market Forecast 2026-2030, 4th Edition, with AI Impact | RNA Therapeutics and Genomics Drive 14.8% CAGR Toward $7.35 Billion
globenewswire.com
ABT
AGNC
AMGN
BDX
BIIB
BMY
CDXS
DHR
DNA
EVO
GILD
HOLX
ILMN
INCY
ISRG
JNJ
LMT
MARA
MRK
NCLH
NTES
ON
ORCL
PFE
QCOM
REGN
ROST
SNOW
TMO
TSLA
TXG
TWST
VRTX
WST
XOM
ZBRA
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight
globenewswire.com
LLY
MRK
GSK
BMY
AZN
PFE
NVO
REGN
RDHL
AGIO
INCY
CRBP
BMRN
VKTX
RIGL
DTIL
CRDF
BIIB
ALKS
EXAS
CLDX
SRPT
TGTX
ALNY
CHKP
TAK
HHS
SERV
GILD
HRMY
IONS
BH
FORM
JNJ
GEN
ABBV
AMGN
CRSP
CHRD
ADPT
IMUX
ALGN
EXEL
VRTX
Peritoneal Cancer - Global Drug Pipeline Analysis and Competitive Landscape, 2026 | 75+ Therapies Drive ADCs, Targeted Therapy, and Immunotherapy Growth Opportunities
globenewswire.com
ABBV
AZN
CELH
INCY
REGN
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
prnewswire.com
MMED
INCY
Global TDP-43 Antibody Market Outlook and Forecast, 2026-2032 - Market to Reach USD 508.93 Million at 12.03% CAGR as Validated Antibodies, AI-Powered Imaging, and Neurodegenerative Research Create New Growth Opportunities
globenewswire.com
ABBV
ABT
ABM
BIO
BIIB
BMRN
CRSP
DHR
EXAS
GILD
ILMN
INCY
ISRG
JNJ
LULU
MDLZ
MRK
NVS
PFE
REGN
ROST
SNPS
SRPT
STX
TMO
TSLA
VRTX
WDC
Mirum Pharmaceuticals e Incyte annunciano l’approvazione da parte dell’FDA statunitense di Atebrioz™ (zilurgisertib) per pazienti adulti e pediatrici affetti da fibrodisplasia ossificante progressiva (FOP)
businesswire.com
MIRM
INCY
Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva
businesswire.com
MIRM
INCY